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CLINICAL, PUBLIC HEALTH,AND ECONOMIC
ISSUES ASSOCIATED WITH SWITCHING
SECOND-GENERATION ANTIHISTAMINES FROM
PRESCRIPTION TO OVER-THE-COUNTER
Prasad M, Shih YCT, Luce BR
MEDTAP International Inc, Bethesda, MD, USA
OBJECTIVE: To compare this switch with prior Rx-
to-OTC switches and discuss its economic, clinical, and
public health implications.
METHODS: The FDA held meetings in May 2001 to
determine if prescription (Rx) second-generation antihis-
tamines (SGAs) should be sold over-the-counter (OTC).
This meeting warranted much attention because a party
other than drug manufacturers requested the switch, and
SGAs’ patents have not expired. Literature reviews of
prior switches and allergic rhinitis (epidemiology and
clinical management) were conducted. Microeconomic
theories were used to examine economic implications of
switching SGAs.
RESULTS: Past experiences of switching drugs to OTC
status (i.e., topical hydrocortisone, H2-blockers) have
resulted in lower prices and greater consumer surplus and
availability. It is unclear if similar conclusions can be
drawn about SGAs, whose patent protection differen-
tiates them from prior switches of patent-expired drugs.
Predictions of the switch’s economic consequences (i.e.,
pricing and social welfare) cannot be made without full
knowledge of demand elasticity in the antihistamine (ﬁrst-
and second-generation) market. Additionally, a mandated
switch prior to patent expiration may discourage research
and development. From a clinical perspective, selling
SGAs OTC may reduce physician intervention, leading 
to drug misuse and missed diagnoses of severe co-
morbidities (e.g., asthma). From a public health perspec-
tive, if SGAs are removed from Rx formularies post-
switch, patients could be responsible for total drug
acquisition costs. This may diminish availability for ﬁnan-
cially vulnerable populations (i.e., Medicaid recipients).
CONCLUSIONS: Selling SGAs OTC may increase avail-
ability and decrease the use of sedating antihistamines.
However, the net impact of their switch remains
unknown. The lack of generic competition implies prices
for SGAs may not fall nor may social welfare improve.
Cost-beneﬁt analyses are needed to determine if beneﬁts
of the switch will outweigh costs of misdiagnoses and
misuse. Lastly, the impact of the switch on vulnerable
populations must also be explored.
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PREGNANCY OUTCOMES IN WOMEN TAKING
ANTI-ASTHMATIC MEDICATIONS IN THE
GEORGIA MEDICAID POPULATION
Joseph GJ1, Kotzan JA2,Wade WE3
1Hines VA Hospital, Hines, IL, USA; 2University of Georgia,
Athens, GA, USA; 3University of Georgia College of
Pharmacy, Athens, GA, USA
OBJECTIVE: To determine the impact of anti-asthmatic
medications on pregnancy outcomes in the Georgia 
Medicaid population.
METHOD: Using Medicaid claims data from Georgia,
we examined pregnancy outcomes over six months from
January to June 1997. Medication and medical history
twelve months prior to each eligible outcome were 
examined. Abnormal pregnancy outcomes included:
spontaneous abortion, hemorrhage, pre-term infant 
and stillborn infants. Logistic regression model included 
pregnancy outcome as the dependent variable. The 
independent variables included age, race, Medicaid 
eligibility, diagnosis for asthma, anti-asthmatic medica-
tion, epilepsy, diabetes, AIDS, anemia, alcohol abuse,
drug abuse, psychosis, depression, tobacco abuse, bipolar
disorders and obesity.
RESULTS: There were 6,396 eligible women who had 
a pregnancy outcome in the six-month study period.
Logistic regression analysis indicated that consumption of
prescription drugs for asthma and other pulmonary con-
ditions increased the risk of an abnormal outcome by
36%. Comorbidities like depression and obesity increased
the risk of an abnormal outcome by 50% and 90%
respectively. Age of 35 or older, had an 89% increase in
abnormal outcomes.
CONCLUSIONS: We showed that women in the Georgia
Medicaid program had an increased risk of an abnormal
pregnancy outcome when using anti-asthmatic medica-
tions during pregnancy. This research has further 
substantiated the possible teratogenic effect hypothesis of
anti-asthmatic medications in pregnancy. Larger cohorts
of women need to be studied over a longer period of time
to fully explore this teratogenic relationship. Results may
have implications for more judicious use of such medica-
tions during pregnancy and for careful pre-natal care for
such women.
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LONG-TERM BENEFITS OF CHEMOPREVENTIVE
TAMOXIFEN AND ROUTINE MAMMOGRAPHY
SCREENING IN WOMEN WHO ARE AT
INCREASED RISK OF BREAST CANCER
Borker R, Madhavan S, Simon K, Higa G,Amonkar M,
Scott V
West Virginia University, Morgantown, WV, USA
